Best Life Sciences Companies in Lexington, United States
The 80 best Life Sciences companies in Lexington, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: T2 Biosystems.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Lexington
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | T2 Biosystems Developer of miniaturized MRI platforms for clinical diagnostics | $454M | 99 mo ago | 166 | 2006 | John Sperzel CEO | — | — |
| 2 | Agenusbio Developer of immunotherapies to treat cancer 60Funding top 20%Tech top 34%Product top 35%Market top 37% All 11 signals ▾Fundingtop 20% Techtop 34% Producttop 35% Markettop 37% Moattop 44% Partnerstop 45% Fin. healthtop 48% Growthtop 50% Newsbottom 47% Talentbottom 40% Globalbottom 39% Funding: Raised $441M across 12 rounds · 12 rounds over 17 yrs (0.7/yr) Tech: 41 technologies across 6/8 capability areas · Cloud: Cloudflare, Fastly rank vs industry peers · Fliar Intelligence Index 60/100 | $441M | 12 mo ago | 533 | 1994 | Garo Armen Chairman & CEO | — | — |
| 3 | Fractyl Provider of Endoscopic procedure for type - 2 diabetes | $345M | 60 mo ago | 79 79 → 106 (+34%) | 2010 | Jay Caplan Co-founder and President | — | — |
| 4 | Kiniksa Pharmaceuticals Developer of therapeutics for multiple diseases treatment | $320M | 97 mo ago | 2 | 2015 | Sanj Patel CEO | — | — |
| 5 | GreenLight Biosciences 🦄 Developer of a platform for RNA-based products for life science industry 69Funding top 23%Growth top 23%Patents top 24%Innovation top 29% All 11 signals ▾Fundingtop 23% Growthtop 23% Patentstop 24% Innovationtop 29% Talenttop 41% Moattop 42% Fin. healthtop 47% Markettop 48% Techbottom 44% Globalbottom 42% Newsbottom 40% Funding: Raised $215M across 12 rounds · 12 rounds over 13 yrs (0.9/yr) Growth: Headcount 163 → 287 (+76%) across vintages · Revenue +325% YoY rank vs industry peers · Fliar Intelligence Index 69/100 | $215M | 14 mo ago | 287 287 → 183 (-36%) | 2008 | Andrey Zarur Co-Founder & CEO | 311 patents RNA‑based biopesticides and plant protection formulations targeting pathogens and insects | — |
| 6 | Accent Therapeutics Developing RNA-modifying protein therapeutics for cancer with significant unmet medical need | $178M | 29 mo ago | 45 45 → 31 (-31%) | 2017 | Robert Copeland President | — | — |
| 7 | Curis Developer of therapeutics by targeting different signaling pathways to treat multiple cancers | $141M | 110 mo ago | 49 | 2000 | Jim Dentzer Chief Executive Officer | 957 patents Combination oncology therapies targeting BCL2 inhibition and checkpoint‑inhibitor‑experienced cancers | 1 partnership |
| 8 | Translate Bio Developer of RNA therapeutics to activate therapeutic protein expression | $138M | 72 mo ago | 209 | 2011 | — | — | — |
| 9 | Synageva Developer of enzyme replacement therapies for rare diseases | $128M | 183 mo ago | 72 | 1996 | Sanj Patel Founder & CEO | — | — |
| 10 | Homology Medicines Developer of gene therapies for rare genetic diseases | $127M | 67 mo ago | 221 | 2015 | Frank Mathias CEO | 162 patents Engineering AAV gene therapy vectors and capsids for liver‑detargeted PAH restoration | — |
| 11 | Taris Biomedical Innovative medicine, therapies, and medical technology for global healthcare solutions | $109M | 102 mo ago | 14 | 2008 | Robert Langer Co-Founder | 720 patents Implantable urological drug‑delivery systems for localized gemcitabine bladder cancer therapy | — |
| 12 | Dicerna Pharmaceuticals Developer of drugs by using RNA interference technology platform | $106M | 90 mo ago | 337 | 2007 | — | 992 patents RNAi therapeutics targeting disease-related genes for metabolic and infectious disorders | — |
| 13 | Outpost Medicine Developer of therapeutics for the treatment of urologic and gynecologic disorders | $97M | 103 mo ago | 4 | 2016 | — | — | — |
| 14 | Microchips Biotech Microchip-based implants for drug delivery | $91M | 132 mo ago | 10 | 1999 | David Koch Co-Founder | 42 patents Implantable microchip drug delivery systems and space‑efficient sealed containment devices | — |
| 15 | Keros Therapeutics Developer of small molecules to treat hematologic and musculoskeletal disorders | $90M | 75 mo ago | 136 136 → 118 (-13%) | 2016 | — | 173 patents Engineered activin receptor and GDNF fusion protein therapeutics for regenerative medicine | — |
| 16 | Synta Pharmaceuticals Small molecule drugs for cancer and chronic inflammatory conditions | $90M | 182 mo ago | 37 | 2000 | — | 1,214 patents HSP90 inhibitor combination therapies for ovarian and other cancers | — |
| 17 | Concert Pharma Developer of multiple drug candidates to treat multiple diseases | $86M | 55 mo ago | 63 | 2006 | — | — | — |
| 18 | scPharmaceuticals Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart… | $79M | 113 mo ago | 96 | 2013 | — | 105 patents Liquid and subcutaneous formulations for delivering furosemide loop diuretic | — |
| 19 | GI Dynamics Developer of endoscopically bile diversion barrier device | $76M | 91 mo ago | 12 | 2003 | — | 704 patents Secure smart-card payment and medical data processing systems for diagnostics and dentistry | — |
| 20 | Verseau Therapeutics Discovering and developing novel cancer treatments | $69M | 80 mo ago | 12 | 2017 | Tatiana Novobrantseva Co-founder and Scientific Advisor | — | — |
| 21 | Pulmatrix Developer of therapeutics for the treatment of respiratory diseases | $67M | 71 mo ago | 28 | 2003 | — | 163 patents Inhalable dry‑powder pharmaceutical formulations for treating pulmonary diseases | — |
| 22 | Hemanext Developer of technologies to store blood and its products 67Patents top 15%Innovation top 17%Moat top 26%Funding top 28% All 10 signals ▾Patentstop 15% Innovationtop 17% Moattop 26% Fundingtop 28% Growthtop 40% Talenttop 43% Techtop 47% Marketbottom 46% Globalbottom 36% Newsbottom 31% Patents: 265 patents matched (strict assignee match) · 194 filings since 2022 vs 65 in 2017-21 Innovation: 265 patents (top 8% of patent-holders) · 194 filings since 2022 vs 65 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $67M | 11 mo ago | 53 53 → 36 (-32%) | 2004 | Martin Cannon Founder | 265 patents Anaerobic blood preservation, pathogen inactivation, and oxygen‑reduction medical device technologies | — |
| 23 | Partner Therapeutics Developer of therapeutics for the treatment of cancer | $60M | 100 mo ago | 168 168 → 187 (+11%) | 2017 | — | — | 4 job openings |
| 24 | RejuvenAir Developer of a cryosurgical device for chronic bronchitis and COPD | $60M | 21 mo ago | 35 | 2006 | — | — | — |
| 25 | GeNO Specialty company developing inhaled drug delivery technologies through its proprietary NO technology | $56M | 105 mo ago | 225 | 2006 | David Fine Founder & Chairman | 200 patents Medical nitric oxide generation and delivery systems for respiratory and cardiovascular therapies | — |
| 26 | Promedior Healthcare innovator providing pharmaceutical and diagnostic solutions for a healthier future | $50M | 164 mo ago | 9 | 2006 | — | 156 patents SAP protein derivatives for anti‑fibrotic and anti‑cancer biologic therapeutics | — |
| 27 | Sideris Pharmaceuticals Therapeutics for the treatment of transfusion-related iron overload. | $50M | 152 mo ago | 5 | 2012 | — | — | — |
| 28 | LogicBio Developer of viral vectors for the treatment of genetic and infectious diseases | $49M | 83 mo ago | 62 | 2013 | Adi Barzel Founder | — | — |
| 29 | Hyalex Developer of a synthetic cartilage platform to restore damaged joint surfaces | $46M | 21 mo ago | 18 18 → 23 (+28%) | 2016 | Carl Vause Chief Executive Officer | — | — |
| 30 | Elpis BioPharmaceuticals Developer of therapeutics targeting the immune response for treating tumors | $40M | 67 mo ago | 18 | 2017 | Yan Chen Founder and CEO | 78 patents CAR‑T immunotherapies targeting B7‑H3, IL‑13Rα2, BCMA/TACI for cancer treatment | — |
| 31 | Tepha Global medical technology company advancing healthcare through innovative solutions and services | $40M | 171 mo ago | 51 | 1998 | — | 627 patents Resorbable polymer medical implants and devices for surgery and aesthetic reconstruction | — |
| 32 | Carbon Biosciences Venture capital firm focused on noval gene therapy | $38M | 48 mo ago | 21 | 2021 | John Engelhardt Co-Founder | — | — |
| 33 | Nexeon MedSystems Bioelectronics company developing neurostimulation devices and software for remote patient management | $28M | 106 mo ago | 48 | 2004 | — | 58 patents Patents concentrated in health & consumer products | — |
| 34 | Avaxia Biologics Developing orally-delivered antibody therapeutics for GI diseases. | $25M | 131 mo ago | 11 | 2005 | — | 52 patents Oral antibody therapeutics targeting TNF for gastrointestinal inflammatory diseases | — |
| 35 | Protein Forest Fractionation technology and bioinformatics software for mass spectrometry | $24M | 199 mo ago | 15 | 2002 | John L. Zabriskie Co-Founder and Director | 21 patents Protein identification and quantification via mass‑spectrometry data analysis and biomolecular arrays | — |
| 36 | N-of-One NGS analysis, interpretation, and reporting solutions for research and clinical applications | $18M | 113 mo ago | 41 | 2008 | — | — | — |
| 37 | Naprogenix Screening and identification of plant compounds for pharmaceuticals and agrochemicals. | $14M | 14 mo ago | 4 | 2002 | Deane Falcone Co-Founder | 2 patents Engineering plant pathways to produce selective estrogen receptor modulators and other metabolites | — |
| 38 | Sentien Biotechnologies Developer of stem cell based device product for acute organ failure | $13M | 110 mo ago | 7 | 2008 | Biju Parekkadan Co-Founder | — | — |
| 39 | iSpecimen Provider of a biorepository of human clinical specimens 24News top 30%Tech top 36%Funding top 42%Partners top 45% All 9 signals ▾Newstop 30% Techtop 36% Fundingtop 42% Partnerstop 45% Growthbottom 44% Moatbottom 41% Marketbottom 38% Globalbottom 32% Fin. healthbottom 22% News: 10 BI events in 12 mo (of 51 tracked, 5 types) · +0% YoY Tech: 38 technologies across 4/8 capability areas · Cloud: Amazon Web Services, Cloudflare rank vs industry peers · Fliar Intelligence Index 24/100 | $12M | 1 mo ago | 75 | 2009 | — | — | — |
| 40 | ParaTechs Corporation Biotechnology company developing innovative technologies for research and development in biotechnology areas | $10M | 14 mo ago | 4 | 2004 | — | — | — |
| 41 | Bioptics Technology Developer of fluorescence imaging devices and cerebral blood flow monitoring systems | $7M | 9 mo ago | — | 2019 | Cindy Sun Founder & CEO | — | — |
| 42 | Gismo Therapeutics Biotech developing innovative oral therapeutics for Alzheimer's and Parkinson's Disease | $6M | 104 mo ago | — | 2011 | Paul Gregor Founder & CEO | — | — |
| 43 | Combinent Biomedical Systems Transvaginal delivery of drugs targeting women’s reproductive endocrinology disorders | $5M | 164 mo ago | — | 2000 | Eric Gordon Founder | — | — |
| 44 | Aldeyra Developer of drugs for the treatment of immune-mediated diseases | $5M | 71 mo ago | 30 | 2004 | — | — | — |
| 45 | Sword Performance Developer of supplements for health and wellness | $4M | 31 mo ago | 11 | 2013 | Shawn Stasko Founder | — | — |
| 46 | Bluegrass Advanced Materials Antioxidant polymers based therapy for the treatment of oral mucositis | $4M | 14 mo ago | 2 | 2013 | Thomas Dziubla Co-Founder | — | — |
| 47 | Hera Biolabs Provider of rodent models for in vitro and in vivo safety and efficacy testing services | $3M | 70 mo ago | 15 | 2015 | — | — | — |
| 48 | Accurius Developer of oncolytic immunotherapy for metastatic non-small cell lung cancer | $3M | 15 mo ago | — | 2019 | Dmitriy Zamarin Co-Founder & CMO | — | — |
| 49 | Hummingbird Nano Manufacturer of microfluidic chips | $2M | 41 mo ago | 10 | 2012 | Grant Stephens CEO | — | — |
| 50 | Omega Ophthalmics Developer of intraocular lens for the treatment of a cataract | $450K | 5 mo ago | — | 2012 | Rick Ifland CEO | 166 patents Intraocular lens capsular bag prosthetic devices for cataract surgery | — |
Top 12 Life Sciences companies in Lexington
#1
Public · Lexington, Massachusetts · founded 1994 · 533 employees$440.7Mraised▾
Developer of immunotherapies to treat cancer. The company's portfolio consists of bio-engineered therapies targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
- Jun 2025Post IPO—
- Jul 2020Post IPO$35M
- Jan 2019Post IPO$30M
- Oct 2018Post IPO$40M
#2
Public · Lexington, Massachusetts · founded 2009 · 75 employees$11.9Mraised▾
iSpecimen is a supplier of human clinical specimens to the therapeutic, diagnostic, and academic research industries. The platform supply researchers with a range of liquid and solid specimens such as plasma, serum, whole blood, urine, CSF, and FFPE blocks and slides. Their customers include researchers in contract research organizations, government agencies, and academic institutions.
- May 2026Post IPO$2.5M
- Dec 2025Post IPO$5.5M
- Aug 2025Post IPO$1.8M
- Nov 2021Post IPO$21M
#3
Public · Lexington, Massachusetts · founded 2008 · 287 employees$215.1Mraised▾
Developer of a platform for RNA-based products for the life science industry. It offer platform that is used for vaccine development, antibody therapies, pandemic preparation, crop management, plant protection, support the health of bees and other pollinators
- Apr 2025Post IPO$25M
- Jul 2024Grant (prize money)$174.3K
- Mar 2024Grant (prize money)$325.1K
- Aug 2022Post IPO$109M
#4
Series B · Lexington, Massachusetts · founded 2004 · 53 employees$67Mraised▾
Developer of technologies to store blood and its products. They have developed 2 distinctive technologies namely Hemanext and MicroVascular Analyzer (measures RBC deformability). Hemanext enables the storage of RBC under anaerobic conditions. It has applications in various therapeutic conditions such as hypercoagulability, inflammation, impaired perfusion, immuno-modulation, etc.
- Jul 2025Series B$18.9M
- Jan 2025Series B$20M
- Nov 2024Series B$21.7M
- Dec 2023Series B$5M
#5
Funding Raised · Lexington, Kentucky · founded 2019$7.2Mraised▾
Developer of fluorescence imaging devices and cerebral blood flow monitoring systems. It designs and builds products that advance medical research. Its offerings include a wearable eye-loupe based fluorescence imaging device for imaging visible dyes, a non-contact tool for 2D/3D imaging of cerebral blood flow and oxygenation, and a wearable diffuse speckle contrast flow-oximetry probe for continuous cerebral blood flow and oxygen saturation monitoring.
- Aug 2025Grant (prize money)$2M
- Mar 2025Grant (prize money)$2.1M
- Sep 2023Grant (prize money)$1M
- Aug 2023Grant (prize money)$1.2M
#6
Series F · Lexington, Massachusetts · founded 2006 · 35 employees$59.7Mraised▾
Developer of a cryosurgical device for chronic bronchitis and COPD. The system delivers small, metered doses of cryogen spray which flash freeze the surface area of damaged airways. It utilizes software-driven dosimetry and catheters to enable the delivery of cryogen spray inside the airways, reducing mucous production, cough, and inflammation in chronic bronchitis and COPD.
- Aug 2024Series F$59.7M
- Feb 2019Conventional Debt$5.1M
- Feb 2019Series E$45.2M
- Oct 2018Series D$8M
#7
Funding Raised · Lexington, Kentucky · founded 2002 · 4 employees$14.1Mraised▾
Naprogenix, Inc., a biotechnology company, provides pharmacological screens to access and screen for plant compounds which can be used for leads for pharmaceuticals and agrochemicals.The company uses its proprietary technology which involves transformation of plant cell, mutagenesis of candidate plant species, identification of the desired tramsformed and mutagenesised cell, followed by isolating extracts, screening and identifying the candidate plant compound. Naprogenix announced the spin off of Solidagex, a new company to commercialize plant beneficial compounds identified from goldenrod based products using its proprietary technology. Naprogenix intends to follow a similar commercialization plan for other products that are identified in wild type plant extracts in its library.
- Apr 2025Grant (prize money)$3.9M
- Sep 2018Grant (prize money)$2.1M
- Nov 2016Grant (prize money)$286K
- Sep 2016Grant (prize money)$456K
#8
Funding Raised · Lexington, Kentucky · founded 2004 · 4 employees$10.4Mraised▾
Biotechnology company developing innovative technologies for research and development in biotechnology areas. They focus on creating novel products to enable advancements in the field. Their offerings include assisted reproductive technology (ART) products for rodents, protein expression products, and a nitrate reductor kit. They are involved in contract research services and seek partnering opportunities through commercial licensing and collaborative research and development. The company's mission is centered around providing solutions for researchers, with a focus on rodent assisted reproduction. They offer devices for non-surgical embryo transfer, artificial insemination, embryo vitrification, and sperm cryopreservation. They also provide technologies for improving recombinant protein production. Their products are intended for research purposes only and not for therapeutic or diagnostic use.
- Apr 2025Grant (prize money)$236.1K
- 2023Grant (prize money)$236.1K
- 2022Grant (prize money)$258.9K
- 2019Grant (prize money)$225K
#9
Series A · Lexington, Massachusetts · founded 2016 · 18 employees$46.4Mraised▾
Developer of a synthetic cartilage platform to restore damaged joint surfaces. The company has developed biomimetic materials that can be used for restoring cartilages during surgery. It can be used for orthopedic implants as well.
- Sep 2024Series A$14.9M
- Mar 2019Series A$15.5M
- May 2017Series A$16M
#10
Series C · Lexington, Massachusetts · founded 2017 · 45 employees$178Mraised▾
Developing RNA-modifying protein therapeutics for cancer with significant unmet medical need. The company focuses on translating extraordinary science into life-changing treatments for cancer patients. It leverages expertise in RNA-modifying protein biology to identify and exploit critical intracellular dependencies across multiple cancer types. They develop small molecule therapeutics designed to inhibit these targets, offering far-reaching potential for patients. Their approach aims to identify high-value programs, both first-in-class and best-in-class, to benefit large patient populations. The company is dedicated to driving the translation of extraordinary science to life-changing therapies. They are focused on innovation in cancer therapeutics, addressing significant unmet medical needs through novel approaches and targeted treatments.
- Jan 2024Series C$75M
- Apr 2020Series B$63M
- Sep 2017Series A$40M
#11
Seed · Lexington, Kentucky · founded 2012$450Kraised▾
Developer of intraocular lens for the treatment of a cataract. The company has developed a proprietary lens known as "Omega Gemini Refractive Capsule" that propels cataract surgery to improve visual rehabilitation.
- Jan 2026Seed$320K
- Dec 2024Seed$250K
- Jul 2022Seed$450K
#12
Funding Raised · Lexington, Kentucky · founded 2013 · 2 employees$3.6Mraised▾
Bluegrass Advanced Materials is developing naturally derived antioxidant polymers for applications in various biotech industries. The company is currently developing an oral treatment for oral inflammation and ulceration (Oral Mucositis) associated with the adverse effects of chemo and radiation therapies.
- Apr 2025Grant (prize money)$1.2M
- Sep 2020Grant (prize money)$746.6K
- Sep 2017Grant (prize money)$169.3K
- Sep 2013Grant (prize money)$1.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.